Letters
Cardiovascular safety of methylphenidate
Cardiovascular safety of methylphenidate should also be considered in adults
BMJ 2016; 353 doi: https://doi.org/10.1136/bmj.i3418 (Published 22 June 2016) Cite this as: BMJ 2016;353:i3418
- François Montastruc1,
- medical pharmacologist,
- Guillaume Montastruc2,
- cardiologist,
- Jean-Louis Montastruc1,
- medical pharmacologist,
- Alexis Revet3,
- child and adolescent psychiatrist
- 1Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d’Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, Toulouse, France
- 2Service de Cardiologie, Clinique des Cèdres Toulouse, Toulouse, France
- 3Service Universitaire de Psychiatrie de l’Enfant et de l’Adolescent, Centre Hospitalier Universitaire Toulouse, UMR 1027 Inserm-Université Paul Sabatier, Toulouse, France
- francois.montastruc{at}univ-tlse3.fr
Shin and colleagues showed an increased risk of arrhythmia from methylphenidate in children and young people with attention-deficit/hyperactivity disorder (ADHD).1 We were recently notified in our clinical unit of a spontaneous adverse drug reaction of ventricular extrasystoles in a 45 year old patient who had been taking methylphenidate alone (36 mg each working day) for two months. A few days after starting treatment he …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.